Your browser doesn't support javascript.
loading
Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases.
Chu, Xiaojie; Sun, Zehua; Baek, Du-San; Li, Wei; Mellors, John W; Shapiro, Steven D; Dimitrov, Dimiter S.
Afiliación
  • Chu X; Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Sun Z; Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Baek DS; Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Li W; Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Mellors JW; Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
  • Shapiro SD; Abound Bio, Pittsburgh, PA 15219, USA.
  • Dimitrov DS; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Int J Mol Sci ; 22(20)2021 Oct 15.
Article en En | MEDLINE | ID: mdl-34681796
Neutrophil elastase (NE) is a serine protease released during neutrophil maturation. High levels of NE are related to lung tissue damage and poor prognosis in cancer; thus, NE is a potential target for therapeutic immunotherapy for multiple lung diseases and cancers. Here, we isolate and characterize two high-affinity, specific, and noncompetitive anti-NE antibodies Fab 1C10 and VH 1D1.43 from two large phage-displayed human Fab and VH libraries. After fusion with human IgG1 Fc, both of them (VH-Fc 1D1.43 and IgG1 1C10) inhibit NE enzymatic activity with VH-Fc 1D1.43 showing comparable inhibitory effects to that of the small molecule NE inhibitor SPCK and IgG1 1C10 exhibiting even higher (2.6-fold) activity than SPCK. Their epitopes, as mapped by peptide arrays combined with structural modeling, indicate different mechanisms for blocking NE activity. Both VH-Fc and IgG1 antibodies block NE uptake by cancer cells and fibroblast differentiation. VH-Fc 1D1.43 and IgG1 1C10 are promising for the antibody-based immunotherapy of cancer and inflammatory diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Elastasa de Leucocito / Proteínas Inhibidoras de Proteinasas Secretoras / Inflamación / Neoplasias Límite: Humans / Male Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Elastasa de Leucocito / Proteínas Inhibidoras de Proteinasas Secretoras / Inflamación / Neoplasias Límite: Humans / Male Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos